variables: 816998
Data license: CC-BY
This data as json
id | name | unit | description | createdAt | updatedAt | code | coverage | timespan | datasetId | sourceId | shortUnit | display | columnOrder | originalMetadata | grapherConfigAdmin | shortName | catalogPath | dimensions | schemaVersion | processingLevel | processingLog | titlePublic | titleVariant | attributionShort | attribution | descriptionShort | descriptionFromProducer | descriptionKey | descriptionProcessing | licenses | license | grapherConfigETL | type | sort | dataChecksum | metadataChecksum |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
816998 | New bacteriologically confirmed pulmonary tuberculosis cases with multidrug-resistant tuberculosis | new cases with MDR-tuberculosis | 2023-12-05 11:52:00 | 2024-07-25 22:54:11 | 2017-2022 | 6308 | { "unit": "new cases with MDR-tuberculosis", "numDecimalPlaces": 0 } |
0 | mdr_new | grapher/tuberculosis/2023-11-27/drug_resistance_surveillance/drug_resistance_surveillance#mdr_new | 2 | major | Number of new bacteriologically confirmed pulmonary tuberculosis cases with multidrug-resistant tuberculosis. Multidrug-resistant tuberculosis is a form of tuberculosis infection caused by bacteria that are resistant to treatment with at least two of the most powerful first-line anti-TB medications (drugs), isoniazid and rifampicin. | Among new tuberculosis patients with available drug susceptibility testing results: number of patients with resistance to isoniazid and rifampicin (MDR-tuberculosis). | [] |
int | [] |
53c6c3f6114cd6d576f9f34cda9446e6 | 1dccb1c49f306623abe7abe542cd60ed |